nodes	percent_of_prediction	percent_of_DWPC	metapath
Alizapride—DRD2—Monoamine GPCRs—ADRA1D—polycystic ovary syndrome	0.0526	0.0526	CbGpPWpGaD
Alizapride—DRD2—Monoamine GPCRs—ADRA1B—polycystic ovary syndrome	0.0512	0.0512	CbGpPWpGaD
Alizapride—DRD2—Amine ligand-binding receptors—ADRA1D—polycystic ovary syndrome	0.0442	0.0442	CbGpPWpGaD
Alizapride—DRD2—Amine ligand-binding receptors—ADRA1B—polycystic ovary syndrome	0.043	0.043	CbGpPWpGaD
Alizapride—DRD2—Monoamine GPCRs—ADRA1A—polycystic ovary syndrome	0.0388	0.0388	CbGpPWpGaD
Alizapride—DRD2—Monoamine GPCRs—ADRB3—polycystic ovary syndrome	0.0373	0.0373	CbGpPWpGaD
Alizapride—DRD2—Nicotine Activity on Dopaminergic Neurons—TH—polycystic ovary syndrome	0.0329	0.0329	CbGpPWpGaD
Alizapride—DRD2—Amine ligand-binding receptors—ADRA1A—polycystic ovary syndrome	0.0326	0.0326	CbGpPWpGaD
Alizapride—DRD2—Amine ligand-binding receptors—ADRB3—polycystic ovary syndrome	0.0314	0.0314	CbGpPWpGaD
Alizapride—DRD2—Circadian rythm related genes—SFTPC—polycystic ovary syndrome	0.027	0.027	CbGpPWpGaD
Alizapride—DRD2—Monoamine GPCRs—ADRB2—polycystic ovary syndrome	0.0202	0.0202	CbGpPWpGaD
Alizapride—DRD2—Amine ligand-binding receptors—ADRB2—polycystic ovary syndrome	0.0169	0.0169	CbGpPWpGaD
Alizapride—DRD2—G alpha (i) signalling events—NPB—polycystic ovary syndrome	0.0144	0.0144	CbGpPWpGaD
Alizapride—DRD2—Circadian rythm related genes—CLDN4—polycystic ovary syndrome	0.0142	0.0142	CbGpPWpGaD
Alizapride—DRD2—G alpha (i) signalling events—PTGER3—polycystic ovary syndrome	0.012	0.012	CbGpPWpGaD
Alizapride—DRD2—Class A/1 (Rhodopsin-like receptors)—NPB—polycystic ovary syndrome	0.0115	0.0115	CbGpPWpGaD
Alizapride—DRD2—Circadian rythm related genes—STAR—polycystic ovary syndrome	0.0112	0.0112	CbGpPWpGaD
Alizapride—DRD2—GPCRs, Class A Rhodopsin-like—PTGER3—polycystic ovary syndrome	0.0112	0.0112	CbGpPWpGaD
Alizapride—DRD2—GPCRs, Class A Rhodopsin-like—LHCGR—polycystic ovary syndrome	0.0112	0.0112	CbGpPWpGaD
Alizapride—DRD2—GPCRs, Class A Rhodopsin-like—PTAFR—polycystic ovary syndrome	0.0105	0.0105	CbGpPWpGaD
Alizapride—DRD2—GPCRs, Class A Rhodopsin-like—ADRA1D—polycystic ovary syndrome	0.0101	0.0101	CbGpPWpGaD
Alizapride—DRD2—GPCRs, Class A Rhodopsin-like—ADRA1B—polycystic ovary syndrome	0.00987	0.00987	CbGpPWpGaD
Alizapride—DRD2—Class A/1 (Rhodopsin-like receptors)—PTGER3—polycystic ovary syndrome	0.00957	0.00957	CbGpPWpGaD
Alizapride—DRD2—Class A/1 (Rhodopsin-like receptors)—LHCGR—polycystic ovary syndrome	0.00957	0.00957	CbGpPWpGaD
Alizapride—DRD2—Class A/1 (Rhodopsin-like receptors)—PTAFR—polycystic ovary syndrome	0.00896	0.00896	CbGpPWpGaD
Alizapride—DRD2—GPCR ligand binding—NPB—polycystic ovary syndrome	0.00874	0.00874	CbGpPWpGaD
Alizapride—DRD2—Class A/1 (Rhodopsin-like receptors)—ADRA1D—polycystic ovary syndrome	0.00869	0.00869	CbGpPWpGaD
Alizapride—DRD2—Class A/1 (Rhodopsin-like receptors)—ADRA1B—polycystic ovary syndrome	0.00846	0.00846	CbGpPWpGaD
Alizapride—DRD2—GPCRs, Class A Rhodopsin-like—FSHR—polycystic ovary syndrome	0.00818	0.00818	CbGpPWpGaD
Alizapride—DRD2—Circadian rythm related genes—MTNR1B—polycystic ovary syndrome	0.00777	0.00777	CbGpPWpGaD
Alizapride—DRD2—GPCRs, Class A Rhodopsin-like—ADRA1A—polycystic ovary syndrome	0.00748	0.00748	CbGpPWpGaD
Alizapride—DRD2—GPCR ligand binding—PTGER3—polycystic ovary syndrome	0.00729	0.00729	CbGpPWpGaD
Alizapride—DRD2—GPCR ligand binding—LHCGR—polycystic ovary syndrome	0.00729	0.00729	CbGpPWpGaD
Alizapride—DRD2—GPCRs, Class A Rhodopsin-like—ADRB3—polycystic ovary syndrome	0.0072	0.0072	CbGpPWpGaD
Alizapride—DRD2—Class A/1 (Rhodopsin-like receptors)—FSHR—polycystic ovary syndrome	0.00701	0.00701	CbGpPWpGaD
Alizapride—DRD2—G alpha (i) signalling events—MTNR1B—polycystic ovary syndrome	0.00685	0.00685	CbGpPWpGaD
Alizapride—DRD2—GPCR ligand binding—PTAFR—polycystic ovary syndrome	0.00682	0.00682	CbGpPWpGaD
Alizapride—DRD2—Circadian rythm related genes—NAMPT—polycystic ovary syndrome	0.00679	0.00679	CbGpPWpGaD
Alizapride—DRD2—GPCR ligand binding—ADRA1D—polycystic ovary syndrome	0.00662	0.00662	CbGpPWpGaD
Alizapride—DRD2—GPCR ligand binding—ADRA1B—polycystic ovary syndrome	0.00644	0.00644	CbGpPWpGaD
Alizapride—DRD2—Class A/1 (Rhodopsin-like receptors)—ADRA1A—polycystic ovary syndrome	0.00641	0.00641	CbGpPWpGaD
Alizapride—DRD2—GPCRs, Class A Rhodopsin-like—MTNR1B—polycystic ovary syndrome	0.00636	0.00636	CbGpPWpGaD
Alizapride—DRD2—Circadian rythm related genes—TOP2A—polycystic ovary syndrome	0.00617	0.00617	CbGpPWpGaD
Alizapride—DRD2—Class A/1 (Rhodopsin-like receptors)—ADRB3—polycystic ovary syndrome	0.00617	0.00617	CbGpPWpGaD
Alizapride—DRD2—Class A/1 (Rhodopsin-like receptors)—LHB—polycystic ovary syndrome	0.0061	0.0061	CbGpPWpGaD
Alizapride—DRD2—Class A/1 (Rhodopsin-like receptors)—GNRH1—polycystic ovary syndrome	0.00596	0.00596	CbGpPWpGaD
Alizapride—DRD2—Circadian rythm related genes—GHRL—polycystic ovary syndrome	0.00574	0.00574	CbGpPWpGaD
Alizapride—DRD2—Circadian rythm related genes—ADIPOQ—polycystic ovary syndrome	0.00556	0.00556	CbGpPWpGaD
Alizapride—DRD2—Class A/1 (Rhodopsin-like receptors)—MTNR1B—polycystic ovary syndrome	0.00545	0.00545	CbGpPWpGaD
Alizapride—DRD2—Circadian rythm related genes—TH—polycystic ovary syndrome	0.00539	0.00539	CbGpPWpGaD
Alizapride—DRD2—GPCR ligand binding—FSHR—polycystic ovary syndrome	0.00534	0.00534	CbGpPWpGaD
Alizapride—DRD2—Circadian rythm related genes—NGFR—polycystic ovary syndrome	0.00505	0.00505	CbGpPWpGaD
Alizapride—DRD2—GPCR downstream signaling—NPB—polycystic ovary syndrome	0.00494	0.00494	CbGpPWpGaD
Alizapride—DRD2—GPCR ligand binding—ADRA1A—polycystic ovary syndrome	0.00488	0.00488	CbGpPWpGaD
Alizapride—DRD2—GPCR ligand binding—ADRB3—polycystic ovary syndrome	0.0047	0.0047	CbGpPWpGaD
Alizapride—DRD2—GPCR ligand binding—LHB—polycystic ovary syndrome	0.00464	0.00464	CbGpPWpGaD
Alizapride—DRD2—GPCR ligand binding—GNRH1—polycystic ovary syndrome	0.00454	0.00454	CbGpPWpGaD
Alizapride—DRD2—Signaling by GPCR—NPB—polycystic ovary syndrome	0.00448	0.00448	CbGpPWpGaD
Alizapride—DRD2—GPCR downstream signaling—PLEKHG5—polycystic ovary syndrome	0.00446	0.00446	CbGpPWpGaD
Alizapride—DRD2—Signaling Pathways—ARHGAP30—polycystic ovary syndrome	0.00437	0.00437	CbGpPWpGaD
Alizapride—DRD2—Signaling Pathways—ARHGAP23—polycystic ovary syndrome	0.00437	0.00437	CbGpPWpGaD
Alizapride—DRD2—GPCR ligand binding—SCT—polycystic ovary syndrome	0.00435	0.00435	CbGpPWpGaD
Alizapride—DRD2—Circadian rythm related genes—NCOR1—polycystic ovary syndrome	0.00419	0.00419	CbGpPWpGaD
Alizapride—DRD2—GPCR ligand binding—MTNR1B—polycystic ovary syndrome	0.00415	0.00415	CbGpPWpGaD
Alizapride—DRD2—GPCR downstream signaling—PTGER3—polycystic ovary syndrome	0.00412	0.00412	CbGpPWpGaD
Alizapride—DRD2—GPCR downstream signaling—LHCGR—polycystic ovary syndrome	0.00412	0.00412	CbGpPWpGaD
Alizapride—DRD2—Signaling by GPCR—PLEKHG5—polycystic ovary syndrome	0.00405	0.00405	CbGpPWpGaD
Alizapride—DRD2—Class A/1 (Rhodopsin-like receptors)—GHRL—polycystic ovary syndrome	0.00403	0.00403	CbGpPWpGaD
Alizapride—DRD2—GPCRs, Class A Rhodopsin-like—ADRB2—polycystic ovary syndrome	0.00389	0.00389	CbGpPWpGaD
Alizapride—DRD2—G alpha (i) signalling events—GNAS—polycystic ovary syndrome	0.00389	0.00389	CbGpPWpGaD
Alizapride—DRD2—GPCR downstream signaling—PTAFR—polycystic ovary syndrome	0.00385	0.00385	CbGpPWpGaD
Alizapride—DRD2—Signaling by GPCR—PTGER3—polycystic ovary syndrome	0.00374	0.00374	CbGpPWpGaD
Alizapride—DRD2—Signaling by GPCR—LHCGR—polycystic ovary syndrome	0.00374	0.00374	CbGpPWpGaD
Alizapride—DRD2—GPCR downstream signaling—ADRA1D—polycystic ovary syndrome	0.00374	0.00374	CbGpPWpGaD
Alizapride—DRD2—GPCR downstream signaling—ADRA1B—polycystic ovary syndrome	0.00364	0.00364	CbGpPWpGaD
Alizapride—DRD2—Signaling by GPCR—PTAFR—polycystic ovary syndrome	0.0035	0.0035	CbGpPWpGaD
Alizapride—DRD2—Circadian rythm related genes—LEP—polycystic ovary syndrome	0.00345	0.00345	CbGpPWpGaD
Alizapride—DRD2—Signaling by GPCR—ADRA1D—polycystic ovary syndrome	0.0034	0.0034	CbGpPWpGaD
Alizapride—DRD2—Class A/1 (Rhodopsin-like receptors)—ADRB2—polycystic ovary syndrome	0.00333	0.00333	CbGpPWpGaD
Alizapride—DRD2—GPCR downstream signaling—PDE3B—polycystic ovary syndrome	0.00331	0.00331	CbGpPWpGaD
Alizapride—DRD2—Signaling by GPCR—ADRA1B—polycystic ovary syndrome	0.00331	0.00331	CbGpPWpGaD
Alizapride—DRD2—GPCR ligand binding—GHRL—polycystic ovary syndrome	0.00307	0.00307	CbGpPWpGaD
Alizapride—DRD2—Signaling Pathways—FLT4—polycystic ovary syndrome	0.00303	0.00303	CbGpPWpGaD
Alizapride—DRD2—GPCR downstream signaling—FSHR—polycystic ovary syndrome	0.00302	0.00302	CbGpPWpGaD
Alizapride—DRD2—Signaling by GPCR—PDE3B—polycystic ovary syndrome	0.00301	0.00301	CbGpPWpGaD
Alizapride—DRD2—Circadian rythm related genes—PPARG—polycystic ovary syndrome	0.00301	0.00301	CbGpPWpGaD
Alizapride—DRD2—GPCR downstream signaling—ADRA1A—polycystic ovary syndrome	0.00276	0.00276	CbGpPWpGaD
Alizapride—DRD2—Signaling by GPCR—FSHR—polycystic ovary syndrome	0.00274	0.00274	CbGpPWpGaD
Alizapride—DRD2—Circadian rythm related genes—SERPINE1—polycystic ovary syndrome	0.00271	0.00271	CbGpPWpGaD
Alizapride—DRD2—GPCR downstream signaling—ADRB3—polycystic ovary syndrome	0.00266	0.00266	CbGpPWpGaD
Alizapride—DRD2—Signaling Pathways—NPB—polycystic ovary syndrome	0.00265	0.00265	CbGpPWpGaD
Alizapride—DRD2—GPCR downstream signaling—LHB—polycystic ovary syndrome	0.00262	0.00262	CbGpPWpGaD
Alizapride—DRD2—G alpha (i) signalling events—POMC—polycystic ovary syndrome	0.00262	0.00262	CbGpPWpGaD
Alizapride—DRD2—GPCR downstream signaling—GNRH1—polycystic ovary syndrome	0.00256	0.00256	CbGpPWpGaD
Alizapride—DRD2—GPCR ligand binding—ADRB2—polycystic ovary syndrome	0.00254	0.00254	CbGpPWpGaD
Alizapride—DRD2—Signaling by GPCR—ADRA1A—polycystic ovary syndrome	0.0025	0.0025	CbGpPWpGaD
Alizapride—DRD2—GPCR downstream signaling—SCT—polycystic ovary syndrome	0.00246	0.00246	CbGpPWpGaD
Alizapride—DRD2—Signaling by GPCR—ADRB3—polycystic ovary syndrome	0.00241	0.00241	CbGpPWpGaD
Alizapride—DRD2—Signaling Pathways—PLEKHG5—polycystic ovary syndrome	0.0024	0.0024	CbGpPWpGaD
Alizapride—DRD2—Signaling by GPCR—LHB—polycystic ovary syndrome	0.00238	0.00238	CbGpPWpGaD
Alizapride—DRD2—GPCR ligand binding—GNAS—polycystic ovary syndrome	0.00235	0.00235	CbGpPWpGaD
Alizapride—DRD2—GPCR downstream signaling—MTNR1B—polycystic ovary syndrome	0.00235	0.00235	CbGpPWpGaD
Alizapride—DRD2—Signaling by GPCR—GNRH1—polycystic ovary syndrome	0.00233	0.00233	CbGpPWpGaD
Alizapride—DRD2—Signaling by GPCR—SCT—polycystic ovary syndrome	0.00223	0.00223	CbGpPWpGaD
Alizapride—DRD2—Signaling Pathways—PTGER3—polycystic ovary syndrome	0.00221	0.00221	CbGpPWpGaD
Alizapride—DRD2—Signaling Pathways—LHCGR—polycystic ovary syndrome	0.00221	0.00221	CbGpPWpGaD
Alizapride—DRD2—Signaling by GPCR—MTNR1B—polycystic ovary syndrome	0.00213	0.00213	CbGpPWpGaD
Alizapride—DRD2—Class A/1 (Rhodopsin-like receptors)—POMC—polycystic ovary syndrome	0.00208	0.00208	CbGpPWpGaD
Alizapride—DRD2—Signaling Pathways—PTAFR—polycystic ovary syndrome	0.00207	0.00207	CbGpPWpGaD
Alizapride—DRD2—Signaling Pathways—ADRA1D—polycystic ovary syndrome	0.00201	0.00201	CbGpPWpGaD
Alizapride—DRD2—Signaling Pathways—ADRA1B—polycystic ovary syndrome	0.00195	0.00195	CbGpPWpGaD
Alizapride—DRD2—Signaling Pathways—INHBB—polycystic ovary syndrome	0.0019	0.0019	CbGpPWpGaD
Alizapride—DRD2—Signaling Pathways—PDE3B—polycystic ovary syndrome	0.00178	0.00178	CbGpPWpGaD
Alizapride—DRD2—GPCR downstream signaling—GHRL—polycystic ovary syndrome	0.00173	0.00173	CbGpPWpGaD
Alizapride—DRD2—Signaling Pathways—FSHR—polycystic ovary syndrome	0.00162	0.00162	CbGpPWpGaD
Alizapride—DRD2—GPCR ligand binding—POMC—polycystic ovary syndrome	0.00158	0.00158	CbGpPWpGaD
Alizapride—DRD2—Signaling by GPCR—GHRL—polycystic ovary syndrome	0.00157	0.00157	CbGpPWpGaD
Alizapride—DRD2—Signaling Pathways—RACGAP1—polycystic ovary syndrome	0.00152	0.00152	CbGpPWpGaD
Alizapride—DRD2—Signaling Pathways—ADRA1A—polycystic ovary syndrome	0.00148	0.00148	CbGpPWpGaD
Alizapride—DRD2—Signaling Pathways—FST—polycystic ovary syndrome	0.00144	0.00144	CbGpPWpGaD
Alizapride—DRD2—GPCR downstream signaling—ADRB2—polycystic ovary syndrome	0.00143	0.00143	CbGpPWpGaD
Alizapride—DRD2—Signaling Pathways—ADRB3—polycystic ovary syndrome	0.00142	0.00142	CbGpPWpGaD
Alizapride—DRD2—Signaling Pathways—LHB—polycystic ovary syndrome	0.00141	0.00141	CbGpPWpGaD
Alizapride—DRD2—Signaling Pathways—GNRH1—polycystic ovary syndrome	0.00138	0.00138	CbGpPWpGaD
Alizapride—DRD2—Signaling Pathways—AKR1C1—polycystic ovary syndrome	0.00133	0.00133	CbGpPWpGaD
Alizapride—DRD2—GPCR downstream signaling—GNAS—polycystic ovary syndrome	0.00133	0.00133	CbGpPWpGaD
Alizapride—DRD2—Signaling Pathways—SCT—polycystic ovary syndrome	0.00132	0.00132	CbGpPWpGaD
Alizapride—DRD2—Signaling by GPCR—ADRB2—polycystic ovary syndrome	0.0013	0.0013	CbGpPWpGaD
Alizapride—DRD2—Circadian rythm related genes—IL6—polycystic ovary syndrome	0.00129	0.00129	CbGpPWpGaD
Alizapride—DRD2—Signaling Pathways—MTNR1B—polycystic ovary syndrome	0.00126	0.00126	CbGpPWpGaD
Alizapride—DRD2—Signaling Pathways—FGF18—polycystic ovary syndrome	0.00124	0.00124	CbGpPWpGaD
Alizapride—DRD2—Signaling Pathways—RBP4—polycystic ovary syndrome	0.00123	0.00123	CbGpPWpGaD
Alizapride—DRD2—Signaling by GPCR—GNAS—polycystic ovary syndrome	0.00121	0.00121	CbGpPWpGaD
Alizapride—DRD2—Signaling Pathways—YAP1—polycystic ovary syndrome	0.00114	0.00114	CbGpPWpGaD
Alizapride—DRD2—Signaling Pathways—GAB1—polycystic ovary syndrome	0.00113	0.00113	CbGpPWpGaD
Alizapride—DRD2—Signaling Pathways—INSR—polycystic ovary syndrome	0.00108	0.00108	CbGpPWpGaD
Alizapride—DRD2—Signaling Pathways—AKR1C3—polycystic ovary syndrome	0.00103	0.00103	CbGpPWpGaD
Alizapride—DRD2—Signaling Pathways—TNRC6B—polycystic ovary syndrome	0.00101	0.00101	CbGpPWpGaD
Alizapride—DRD2—Signaling Pathways—PGR—polycystic ovary syndrome	0.001	0.001	CbGpPWpGaD
Alizapride—DRD2—Signaling Pathways—GHRL—polycystic ovary syndrome	0.000929	0.000929	CbGpPWpGaD
Alizapride—DRD2—Signaling Pathways—PLAT—polycystic ovary syndrome	0.000929	0.000929	CbGpPWpGaD
Alizapride—DRD2—GPCR downstream signaling—POMC—polycystic ovary syndrome	0.000895	0.000895	CbGpPWpGaD
Alizapride—DRD2—Signaling Pathways—ATF1—polycystic ovary syndrome	0.000886	0.000886	CbGpPWpGaD
Alizapride—DRD2—Signaling Pathways—TCF7L2—polycystic ovary syndrome	0.000864	0.000864	CbGpPWpGaD
Alizapride—DRD2—GPCR downstream signaling—AKT2—polycystic ovary syndrome	0.00086	0.00086	CbGpPWpGaD
Alizapride—DRD2—Signaling Pathways—NGFR—polycystic ovary syndrome	0.000818	0.000818	CbGpPWpGaD
Alizapride—DRD2—Signaling by GPCR—POMC—polycystic ovary syndrome	0.000813	0.000813	CbGpPWpGaD
Alizapride—DRD2—Signaling Pathways—PRL—polycystic ovary syndrome	0.000811	0.000811	CbGpPWpGaD
Alizapride—DRD2—Signaling by GPCR—AKT2—polycystic ovary syndrome	0.000781	0.000781	CbGpPWpGaD
Alizapride—DRD2—Signaling Pathways—ADRB2—polycystic ovary syndrome	0.000769	0.000769	CbGpPWpGaD
Alizapride—DRD2—Signaling Pathways—GNAS—polycystic ovary syndrome	0.000713	0.000713	CbGpPWpGaD
Alizapride—DRD2—Signaling Pathways—NCOR1—polycystic ovary syndrome	0.000679	0.000679	CbGpPWpGaD
Alizapride—DRD2—Signaling Pathways—NRG1—polycystic ovary syndrome	0.000667	0.000667	CbGpPWpGaD
Alizapride—DRD2—Signaling Pathways—IRS2—polycystic ovary syndrome	0.000571	0.000571	CbGpPWpGaD
Alizapride—DRD2—Signaling Pathways—LEP—polycystic ovary syndrome	0.000559	0.000559	CbGpPWpGaD
Alizapride—DRD2—Signaling Pathways—IRS1—polycystic ovary syndrome	0.000499	0.000499	CbGpPWpGaD
Alizapride—DRD2—Signaling Pathways—POMC—polycystic ovary syndrome	0.00048	0.00048	CbGpPWpGaD
Alizapride—DRD2—Signaling Pathways—INS—polycystic ovary syndrome	0.000478	0.000478	CbGpPWpGaD
Alizapride—DRD2—Signaling Pathways—IGF1—polycystic ovary syndrome	0.000462	0.000462	CbGpPWpGaD
Alizapride—DRD2—Signaling Pathways—AKT2—polycystic ovary syndrome	0.000462	0.000462	CbGpPWpGaD
Alizapride—DRD2—Signaling Pathways—SERPINE1—polycystic ovary syndrome	0.000439	0.000439	CbGpPWpGaD
Alizapride—DRD2—Signaling by GPCR—IL6—polycystic ovary syndrome	0.000353	0.000353	CbGpPWpGaD
Alizapride—DRD2—Signaling Pathways—VEGFA—polycystic ovary syndrome	0.000302	0.000302	CbGpPWpGaD
Alizapride—DRD2—Signaling Pathways—IL6—polycystic ovary syndrome	0.000209	0.000209	CbGpPWpGaD
